Carsyon, the Strategic Business Unit of Micro Labs Ltd, which deals with drugs for the management of cardio-diabetic diseases is gearing up launch two brands. One of them Vitamer-EA will be available in the market by the end of this month, while the other Amlong MT will be introduced in November.

Both the brands are being launched only in the domestic market at a juncture where an alarming number of Indians are being diagnosed with diabetes and heart diseases, stated S Hariharan, Sr VP - Carsyon, Micro Labs.

Amlong MT is the choicest option in the treatment of various heart conditions like hypertension, angina and coronary artery disease, whereas Vitamin-EA contains two essential antioxidants - Benfotiamine and L-Carnosine. This combination which can effectively prevent complications associated with heart disease and diabetes is being launched for the first time in India by Micro Labs, said Hariharan.

Carsyon division formed in 1994 with a focus only on cardio-diabetes drugs. Its potfolio comprises 22 products. The division has generated Rs 100 crore to the total turnover of the Rs 850 crore of Micro Labs group.

Micro Labs manufactures and markets a wide range of products for a variety of therapies and age groups. With over 300 widely accepted brands under its label and many more in the pipeline, the company is clearly set to lead the pharma revolution in the years to come. Its therapy areas are cardiovascular, gynaecology, gastroenterology, dermatology, ophthalmology, neuro psychiatry anti diabetic, antimicrobials, antiseptics, nutraceutical, analgesics/antipyretic and anti-malarias.

The company which invested Rs 25 crore to set up a formulation unit at Baddi in Himachal Pradesh to take advantage of the excise free status has commissioned the unit in last June.